Annual FCF
-$25.34 M
+$3.86 M+13.22%
December 31, 2023
Summary
- As of February 8, 2025, VYNE annual free cash flow is -$25.34 million, with the most recent change of +$3.86 million (+13.22%) on December 31, 2023.
- During the last 3 years, VYNE annual FCF has risen by +$111.85 million (+81.53%).
- VYNE annual FCF is now -1003.70% below its all-time high of -$2.30 million, reached on December 31, 2016.
Performance
VYNE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$8.51 M
-$29.00 K-0.34%
September 30, 2024
Summary
- As of February 8, 2025, VYNE quarterly free cash flow is -$8.51 million, with the most recent change of -$29.00 thousand (-0.34%) on September 30, 2024.
- Over the past year, VYNE quarterly FCF has dropped by -$29.00 thousand (-0.34%).
- VYNE quarterly FCF is now -23100.00% below its all-time high of $37.00 thousand, reached on June 30, 2017.
Performance
VYNE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$30.11 M
-$3.36 M-12.55%
September 30, 2024
Summary
- As of February 8, 2025, VYNE TTM free cash flow is -$30.11 million, with the most recent change of -$3.36 million (-12.55%) on September 30, 2024.
- Over the past year, VYNE TTM FCF has dropped by -$3.36 million (-12.55%).
- VYNE TTM FCF is now -442.82% below its all-time high of -$5.55 million, reached on June 30, 2017.
Performance
VYNE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
VYNE Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.2% | -0.3% | -12.6% |
| 3 y3 years | +81.5% | -76.9% | -3.1% |
| 5 y5 years | +52.1% | -76.9% | -3.1% |
VYNE Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +55.0% | -76.9% | +15.1% | -20.4% | +46.6% |
| 5 y | 5-year | at high | +81.5% | -76.9% | +83.7% | -20.4% | +78.0% |
| alltime | all time | -1003.7% | +81.5% | <-9999.0% | +83.7% | -442.8% | +78.0% |
VYNE Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.51 M(+0.3%) | -$30.11 M(+12.6%) |
| Jun 2024 | - | -$8.48 M(+6.3%) | -$26.75 M(-3.9%) |
| Mar 2024 | - | -$7.98 M(+55.4%) | -$27.84 M(+9.9%) |
| Dec 2023 | -$25.34 M(-13.2%) | -$5.14 M(-0.3%) | -$25.34 M(+1.3%) |
| Sep 2023 | - | -$5.15 M(-46.2%) | -$25.02 M(-7.3%) |
| Jun 2023 | - | -$9.57 M(+74.8%) | -$26.99 M(+5.3%) |
| Mar 2023 | - | -$5.48 M(+13.9%) | -$25.64 M(-12.2%) |
| Dec 2022 | -$29.20 M(-48.2%) | -$4.81 M(-32.5%) | -$29.20 M(-15.1%) |
| Sep 2022 | - | -$7.13 M(-13.4%) | -$34.41 M(-23.2%) |
| Jun 2022 | - | -$8.22 M(-9.0%) | -$44.82 M(-15.2%) |
| Mar 2022 | - | -$9.04 M(-9.8%) | -$52.85 M(-6.2%) |
| Dec 2021 | -$56.37 M(-58.9%) | -$10.02 M(-42.9%) | -$56.37 M(-21.4%) |
| Sep 2021 | - | -$17.54 M(+7.9%) | -$71.72 M(-7.8%) |
| Jun 2021 | - | -$16.26 M(+29.5%) | -$77.82 M(-20.2%) |
| Mar 2021 | - | -$12.55 M(-50.5%) | -$97.49 M(-28.9%) |
| Dec 2020 | -$137.19 M | -$25.38 M(+7.4%) | -$137.19 M(+7.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$23.64 M(-34.2%) | -$128.23 M(+6.0%) |
| Jun 2020 | - | -$35.93 M(-31.2%) | -$120.97 M(+21.8%) |
| Mar 2020 | - | -$52.25 M(+218.3%) | -$99.29 M(+52.5%) |
| Dec 2019 | -$65.11 M(+23.1%) | -$16.41 M(+0.2%) | -$65.11 M(-0.3%) |
| Sep 2019 | - | -$16.38 M(+15.0%) | -$65.34 M(+6.7%) |
| Jun 2019 | - | -$14.24 M(-21.2%) | -$61.25 M(+2.5%) |
| Mar 2019 | - | -$18.07 M(+8.6%) | -$59.75 M(+13.0%) |
| Dec 2018 | -$52.87 M(+87.2%) | -$16.64 M(+35.4%) | -$52.87 M(+13.9%) |
| Sep 2018 | - | -$12.29 M(-3.5%) | -$46.40 M(-0.5%) |
| Jun 2018 | - | -$12.74 M(+13.7%) | -$46.65 M(+37.7%) |
| Mar 2018 | - | -$11.20 M(+10.2%) | -$33.87 M(+19.9%) |
| Dec 2017 | -$28.25 M(+1130.4%) | -$10.17 M(-18.9%) | -$28.25 M(+56.2%) |
| Sep 2017 | - | -$12.53 M(<-9900.0%) | -$18.08 M(+225.9%) |
| Jun 2017 | - | $37.00 K(-100.7%) | -$5.55 M(-0.7%) |
| Mar 2017 | - | -$5.58 M | -$5.58 M |
| Dec 2016 | -$2.30 M(-45.1%) | - | - |
| Dec 2015 | -$4.18 M | - | - |
FAQ
- What is VYNE Therapeutics annual free cash flow?
- What is the all time high annual FCF for VYNE Therapeutics?
- What is VYNE Therapeutics annual FCF year-on-year change?
- What is VYNE Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly FCF year-on-year change?
- What is VYNE Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for VYNE Therapeutics?
- What is VYNE Therapeutics TTM FCF year-on-year change?
What is VYNE Therapeutics annual free cash flow?
The current annual FCF of VYNE is -$25.34 M
What is the all time high annual FCF for VYNE Therapeutics?
VYNE Therapeutics all-time high annual free cash flow is -$2.30 M
What is VYNE Therapeutics annual FCF year-on-year change?
Over the past year, VYNE annual free cash flow has changed by +$3.86 M (+13.22%)
What is VYNE Therapeutics quarterly free cash flow?
The current quarterly FCF of VYNE is -$8.51 M
What is the all time high quarterly FCF for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly free cash flow is $37.00 K
What is VYNE Therapeutics quarterly FCF year-on-year change?
Over the past year, VYNE quarterly free cash flow has changed by -$29.00 K (-0.34%)
What is VYNE Therapeutics TTM free cash flow?
The current TTM FCF of VYNE is -$30.11 M
What is the all time high TTM FCF for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM free cash flow is -$5.55 M
What is VYNE Therapeutics TTM FCF year-on-year change?
Over the past year, VYNE TTM free cash flow has changed by -$3.36 M (-12.55%)